You are not logged in. FreshNews.com enhanced features available with FREE registration!

EnglandPR NewswireReportBuyer
background image

Global Anticoagulants Industry

Posted: May 11, 2016 3:15 am (UTC)

LONDON, May 10, 2016 /PRNewswire/ — This report analyzes the worldwide markets for Anticoagulants in US$ Million by the following Segments: Oral Anticoagulants, and Injectable Anticoagulants (Unfractionated Heparin, and Low Molecular Weight Heparin). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 51companies including many key and niche players such as –

Abbott India Limited
Aspen Holdings
Bayer Healthcare AG
Boehringer Ingelheim
Bristol-Myers Squibb Company

Download the full report: https://www.reportbuyer.com/product/98261/

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations I-1 Disclaimers………….. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Oral Anticoagulants…………..I-3 Injectable Anticoagulants…………..I-3

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW…………..II-1 Anticoagulants Market Driven by Novel Oral Anti-coagulants II-1 Safety Issues Associated with Erstwhile Market Leaders – Warfarin & Heparins…………..II-2 Anticoagulants – Evolution from Injectables to Oral Drugs II-2 Conventional Oral Drugs Face the Heat II-3 The Newer Breed of NOACs…………..II-3 Comparative Analysis of Warfarin and Novel Oral Anticoagulants II-4 Table 1: Global Market for Leading Oral Drugs (2014): Percentage Market Share Breakdown of Value Sales for Eliquis, Pradaxa, Xarelto, and Others (includes corresponding Graph/Chart)…………..II-5 Novel Oral Drugs: Absence of Antidote & Other Concerns II-5 Rapid Ongoing R&D on Antidote Development II-5 Pipeline of Antidotes to Reverse Anticoagulant Action II-6 Aging Population: Crucial Driver for Anticoagulants Market II-6 Table 2: Global Population Statistics for 65+ Age Group (2014) (includes corresponding Graph/Chart) II-7

Table 3: Elderly Population (65+ Years) Worldwide by Geographic Region on the Basis of Economic Status (2000 & 2025): % of Total Population for More Developed Countries, Less Developed Countries and Least Developed Countries (includes corresponding Graph/Chart) II-8

Table 4: Life Expectancy for Select Countries in Number of Years (2015E) (includes corresponding Graph/Chart) II-9 Rising Stroke Statistics – An Opportunity Indicator for Anticoagulants………….. II-10 Global Menace of Cardiovascular Disease – Major Growth Factor II-10 Table 5: Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart) II-11

Table 6: Fatalities by Heart Conditions – Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others (includes corresponding Graph/Chart)………….. II-11 Sizing the Market………….. II-11 No Immediate Threat of Generics for NOACs II-12 Market Players………….. II-12 Betrixaban – The Only Other Novel Oral Drug in Pipeline II-12

2. MARKET TRENDS & ISSUES…………..II-13 NICE Guidelines Promote NOAC Usage II-13 NOACs as Alternative/Supplement to Antiplatelet Therapy II-13 Increase in Heparin Trade Boosts the Market II-14 NOAC Underdosing Trend Restrains Universal Acceptance II-14 Generics Prevail in the Traditional Market II-15 Patent Expiries of Traditional Anticoagulants in the US II-15 Inadequate Trials Mar Pediatric Anticoagulants Market II-15 Growing Demand for Self-Testing…………..II-16 LMWHs Ease Outpatient Management II-16

3. SEGMENT ANALYSIS………….. II-17 Oral Anticoagulant Agents…………..II-17 Traditional Oral Anticoagulants…………..II-17 Warfarin………….. II-17 Coumadin – The Branded Warfarin II-17 Advantages and Alternatives…………..II-18 Side Effects………….. II-18 Limitations………….. II-18 Novel Oral AntiCoagulants (NOAC) II-19 Approved Indications of Various NOACs by Geographic Region II-19 Approved Anticoagulant Agents in a Nutshell II-19 Pradaxa (Dabigatran Etexilate)…………..II-20 Pradaxa and Warfarin – A Comparative Study II-20 Xarelto (Rivaroxaban)…………..II-20 Apixaban (Eliquis)………….. II-21 Injectable Anticoagulants…………..II-22 Injectable Anticoagulants- An Insight II-22 Heparin – The Backbone of Injectable Anticoagulants II-22 Unfractionated Heparin…………..II-23 Advantages and Alternatives II-23 Limitations………….. II-23 Low Molecular Weight Heparins…………..II-23 Indications………….. II-24 Advantages………….. II-24 A Focus on Select Heparin-based Injectables II-25 Lovenox/Clexane (enoxaparin)…………..II-25 Fragmin (dalteparin sodium) II-26 Fraxiparine (nadroparin)…………..II-26 Innohep (tinzaparin)…………..II-26 Normiflo (ardeparin)…………..II-27 Clivarine (reviparin)…………..II-27 Non-Heparin Anticoagulant Injectables – An Overview II-27 Arixtra (fondaparinux)…………..II-27 Angiomax (bivalirudin)…………..II-28 Argatroban/Novastan…………..II-28

4. THERAPEUTIC INDICATIONS…………..II-30 Venous/DVT Thrombosis Indications II-30 Venous Thromboembolism…………..II-30 Deep Vein Thrombosis…………..II-30 Pulmonary Embolism…………..II-30 Orthopedic (Hip or Knee Replacement) Surgery II-31 General Surgery………….. II-31 Cancer………….. II-31 Arterial Thrombosis Indications…………..II-31 Arterial Thrombosis…………..II-31 Acute Coronary Syndromes…………..II-32 Atrial Fibrillation…………..II-32 Unstable Angina………….. II-32 List of Approved Anticoagulants for Unstable Angina II-33 Myocardial Infarction…………..II-33 Non ST-Segment Elevation MI…………..II-33 Percutaneous Transluminal Coronary Angioplasty (PTCA) II-33 Heparin Induced Thrombocytopenia (HIT) Indications II-34 Heparin Induced Thrombocytopenia with Thrombosis (HITTS) II-34 Other Indications………….. II-35 Hemodialysis………….. II-35

5. PRODUCT INTRODUCTIONS/APPROVALS II-36 FDA Approves Pradaxa Antidote Praxbind II-36 CFDA Approves Bayer’s Xarelto…………..II-36 Raplixa Anticoagulant by MDCO Receives FDA Approval II-36 Teva Launches Argatroban Injection in the US Market II-36 BMS and Pfizer Announce Phase III Results of Apixaban II-36 Boehringer Ingelheim Receives Priority Review by FDA for Idarucizumab BLA………….. II-36 FDA Grants Fast Track Designation to Perosphere’s PER977 II-36 FDA Approves Savaysa/Edoxaban…………..II-37 FDA Approves sNDA for Eliquis…………..II-37 USFDA Approves Pradaxa by Boehringer Ingelheim II-37 EC Approves Expanded Indications of Xarelto II-37

6. RECENT INDUSTRY ACTIVITY…………..II-38 Bayer Collaborates with Janssen on Extended Clinical Investigation of Xarelto…………..II-38 Bayer to Acquire Experimental Anticoagulant from Isis Pharmaceuticals………….. II-38 Akers Biosciences Receives Supply Order from NovoTek for PIFA Heparin PF4………….. II-38 Mylan Ireland to Acquire Arixtra Generic Rights from Aspen II-38 Merus Labs Acquires Sintrom (acenocoumarol) from Novartis AG II-38 CMC Biologics Signs Supply Agreement with Portola Pharmaceuticals II-38 GlaxoSmithKline Divests Thrombosis Brands to Aspen II-39 SQI Diagnostics Partners with Algorithme Pharma on Multiplex Heparin Assay………….. II-39

7. FOCUS ON SELECT GLOBAL PLAYERS…………..II-40 Abbott India Limited (India)…………..II-40 Aspen Holdings (South Africa)…………..II-40 Bayer Healthcare AG (Germany)…………..II-40 Boehringer Ingelheim (Germany) II-41 Bristol-Myers Squibb Company (US) II-41 Eisai Inc. (US)………….. II-42 GlaxoSmithKline Plc. (UK)…………..II-42 Mitsubishi Tanabe Pharma Corporation (Japan) II-42 Pfizer, Inc. (US)………….. II-43 Sanofi S.A. (France)…………..II-43 Teva Pharmaceutical Industries Ltd. (Israel) II-44

8. GLOBAL MARKET PERSPECTIVE…………..II-45 Table 7: World Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)…………..II-45

Table 8: World Historic Review for Anticoagulants by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)………….. II-46

Table 9: World 14-Year Perspective for Anticoagulants by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) II-47

Table 10: World Recent Past, Current & Future Analysis for Oral Anticoagulants by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)…………..II-48

Table 11: World Historic Review for Oral Anticoagulants by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)………….. II-49

Table 12: World 14-Year Perspective for Oral Anticoagulants by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) II-50

Table 13: World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)…………..II-51

Table 14: World Historic Review for Injectable Anticoagulants by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)………….. II-52

Table 15: World 14-Year Perspective for Injectable Anticoagulants by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) II-53

Table 16: World Recent Past, Current & Future Analysis for Injectable Anticoagulants by Product Segment – Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) II-54

Table 17: World Historic Review for Injectable Anticoagulants by Product Segment – Unfractionated Heparin and Low Molecular Weight Heparin Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) II-55

Table 18: World 14-Year Perspective for Injectable Anticoagulants by Product Segment – Percentage Breakdown of Dollar Sales for Unfractionated Heparin and Low Molecular Weight Heparin Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)…………..II-56

Table 19: World Recent Past, Current & Future Analysis for Unfractionated Heparin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)…………..II-57

Table 20: World Historic Review for Unfractionated Heparin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)………….. II-58

Table 21: World 14-Year Perspective for Unfractionated Heparin by Geographic Region/Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) II-59

Table 22: World Recent Past, Current & Future Analysis for Low Molecular Weight Heparin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)…………..II-60

Table 23: World Historic Review for Low Molecular Weight Heparin by Geographic Region/Country – US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)………….. II-61

Table 24: World 14-Year Perspective for Low Molecular Weight Heparin by Geographic Region/ Country – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) II-62

III. MARKET

1. THE UNITED STATES………….. III-1 A.Market Analysis………….. III-1 Key Statistics………….. III-1 US: The Largest Market for Anti-Coagulants III-1 A List of FDA Approved Anticoagulants III-2 Atrial Fibrillation – A Key Risk Factor III-2 Rapidly Ageing Demographics Drive Growth in the Anticoagulants Market…………..III-3 Table 25: North American Aging Population by Age Group: 1975-2050 (includes corresponding Graph/Chart) III-3 Surge in CVD Incidence – Major Growth Factor III-4 Table 26: CVD in the US: Cardiovascular Disease Prevalence in Adults by Gender & Age Group (includes corresponding Graph/Chart)………….. III-4

Table 27: CVD in the US: Cardiovascular Disease Incidence by Gender & Age Group (per 1,000 Adults) (includes corresponding Graph/Chart)…………..III-5

Table 28: Leading Causes of CVD Fatalities in the US: Percentage Breakdown of Mortality for Coronary Heart Disease, HBP, Heart Failure, Stroke, and Others (includes corresponding Graph/Chart)…………..III-5 Lack of Public Health Funding…………..III-5 Table 29: US Healthcare Spending by Therapeutic Area (2014): Percentage Share Breakdown of Expenditure for Various Therapeutic Areas (includes corresponding Graph/Chart)………….. III-6 US Heparin Market………….. III-6 Heparin Trade Statistics…………..III-7 Table 30: The US Exports of Heparin & its Salts; Human/Animal Substances for Therapeutic Uses (2014 & 2013): Percentage Share Breakdown of Export Value of Leading Destination Countries (includes corresponding Graph/Chart) III-7

Table 31: The US Imports of Heparin & its Salts; Human/Animal Substances for Therapeutic Uses (2014 & 2013): Percentage Share Breakdown of Import Value of Leading Countries of Origin (includes corresponding Graph/Chart) III-8 Product Introductions/Approvals III-9 Strategic Corporate Developments III-10 Select Key Players…………..III-10 B.Market Analytics…………..III-12 Table 32: The US Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-12

Table 33: The US Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-13

Table 34: The US 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-14

2. CANADA………….. III-15 A.Market Analysis………….. III-15 Heparin Trade Statistics…………..III-15 Table 35: Canadian Exports of Heparin & its Salts; Human/Animal Substances for Therapeutic Uses (2014 & 2013): Percentage Share Breakdown of Export Value of Leading Destination Countries (includes corresponding Graph/Chart) III-15

Table 36: Canadian Imports of Heparin & its Salts; Human/Animal Substances for Therapeutic Uses (2014 & 2013): Percentage Share Breakdown of Import Value of Leading Countries of Origin (includes corresponding Graph/Chart) III-16 B.Market Analytics…………..III-17 Table 37: Canadian Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-17

Table 38: Canadian Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-18

Table 39: Canadian 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-19

3. JAPAN………….. III-20 A.Market Analysis………….. III-20 Graying Population Spurs Growth of Anticoagulants III-20 Table 40: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart) III-20

Table 41: Aging Population Growth (%) in Japan: 2015E-2060P (includes corresponding Graph/Chart) III-21 Select Key Players…………..III-21 B.Market Analytics…………..III-23 Table 42: Japanese Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-23

Table 43: Japanese Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-24

Table 44: Japanese 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-25

4. EUROPE………….. III-26 A.Market Analysis………….. III-26 Europe: A Major Anti-Coagulant Market III-26 Differential Uptake of NOACs by European Countries III-26 Table 45: European Percentage Uptake of NOACs by Country: 2014 (includes corresponding Graph/Chart) III-27 Increasing Aging Population Boosts Demand III-27 Table 46: Life Expectancy at 65 Years for Select Countries in Europe: 2012 (includes corresponding Graph/Chart) III-28

Table 47: European Population by Age Group (2014): Percentage Share Breakdown of Age groups 0-19, 20-39, 40-59, 60-79, and 80+ (includes corresponding Graph/Chart) III-29 LMWH: Dominant Heparin Segment in Europe III-29 B.Market Analytics…………..III-30 Table 48: European Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country – France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)…………..III-30

Table 49: European Historic Review for Anticoagulants by Geographic Region/Country – France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-31

Table 50: European 14-Year Perspective for Anticoagulants by Geographic Region/Country – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)…………..III-32

Table 51: European Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-33

Table 52: European Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-34

Table 53: European 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-35

4a. FRANCE………….. III-36 A.Market Analysis………….. III-36 Sanofi S.A. – A Key Player…………..III-36 B.Market Analytics…………..III-37 Table 54: French Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-37

Table 55: French Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-38

Table 56: French 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-39

4b. GERMANY………….. III-40 A.Market Analysis………….. III-40 Product Launches…………..III-40 Strategic Corporate Developments III-41 Focus on Select Players…………..III-41 B.Market Analytics…………..III-43 Table 57: German Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-43

Table 58: German Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-44

Table 59: German 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-45

4c. ITALY………….. III-46 Market Analysis………….. III-46 Table 60: Italian Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-46

Table 61: Italian Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-47

Table 62: Italian 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-48

4d. THE UNITED KINGDOM…………..III-49 A.Market Analysis………….. III-49 Stroke Statistics – Opportunity Indicator for Anticoagulants III-49 NICE Guidelines Promote NOAC Usage III-49 Strategic Corporate Development III-50 GlaxoSmithKline Plc. – A Key Player III-50 B.Market Analytics…………..III-51 Table 63: The UK Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-51

Table 64: The UK Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-52

Table 65: The UK 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-53

4e. SPAIN………….. III-54 Market Analysis………….. III-54 Table 66: Spanish Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-54

Table 67: Spanish Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-55

Table 68: Spanish 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-56

4f. RUSSIA………….. III-57 Market Analysis………….. III-57 Table 69: Russian Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-57

Table 70: Russian Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-58

Table 71: Russian 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-59

4g. REST OF EUROPE………….. III-60 A.Market Analysis………….. III-60 Strategic Corporate Development III-60 B.Market Analytics…………..III-61 Table 72: Rest of European Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)………….. III-61

Table 73: Rest of European Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-62

Table 74: Rest of European 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-63

5. ASIA-PACIFIC………….. III-64 A.Market Analysis………….. III-64 Highly Populated Asian Countries Offer Significant Growth Opportunities………….. III-64 Table 75: Population Statistics in Select Asian Countries & Percentage of Population Aged Above 65 Years (includes corresponding Graph/Chart)…………..III-64 B.Market Analytics…………..III-65 Table 76: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country – China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-65

Table 77: Asia-Pacific Historic Review for Anticoagulants by Geographic Region/Country – China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-66

Table 78: Asia-Pacific 14-Year Perspective for Anticoagulants by Geographic Region/Country – Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)…………..III-67

Table 79: Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)………….. III-68

Table 80: Asia-Pacific Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-69

Table 81: Asia-Pacific 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-70

5a. CHINA………….. III-71 A.Market Analysis………….. III-71 Favorable Reimbursement for NOACs III-71 LMWH – The leading Heparin Segment III-71 Table 82: Chinese Import & Export Volumes and Values of Heparin & its Salts (2013, 2014 & 2015): Total Import Volume & Total Export Volume (in Kg); and Total Import Value & Total Export Value (in US$) III-71 Product Approval…………..III-72 Strategic Corporate Development III-72 B.Market Analytics…………..III-73 Table 83: Chinese Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-73

Table 84: Chinese Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-74

Table 85: Chinese 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-75

5b. INDIA………….. III-76 A.Market Analysis………….. III-76 Abbott India Limited – A Key Player III-76 B.Market Analytics…………..III-77 Table 86: Indian Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-77

Table 87: Indian Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-78

Table 88: Indian 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-79

5c. REST OF ASIA-PACIFIC…………..III-80 Market Analysis………….. III-80 Table 89: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)………….. III-80

Table 90: Rest of Asia-Pacific Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-81

Table 91: Rest of Asia-Pacific 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-82

6. LATIN AMERICA………….. III-83 Market Analysis………….. III-83 Table 92: Latin American Recent Past, Current & Future Analysis for Anticoagulants by Geographic Region/Country – Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-84

Table 93: Latin American Historic Review for Anticoagulants by Geographic Region/Country – Brazil and Rest of Latin American Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)…………..III-85

Table 94: Latin American 14-Year Perspective for Anticoagulants by Geographic Region/Country – Percentage Breakdown of Dollar Sales for Brazil and Rest of Latin American Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)…………..III-86

Table 95: Latin American Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)………….. III-87

Table 96: Latin American Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-88

Table 97: Latin American 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-89

6a. BRAZIL………….. III-90 Market Analysis………….. III-90 Table 98: Brazilian Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart) III-90

Table 99: Brazilian Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-91

Table 100: Brazilian 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)………….. III-92

6b. REST OF LATIN AMERICA…………..III-93 Market Analysis………….. III-93 Table 101: Rest of Latin American Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)………….. III-93

Table 102: Rest of Latin American Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-94

Table 103: Rest of Latin American 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-95

7. REST OF WORLD………….. III-96 A.Market Analysis………….. III-96 Teva Pharmaceutical Industries Ltd – A Key Player (Israel) III-96 B.Market Analytics…………..III-97 Table 104: Rest of World Recent Past, Current & Future Analysis for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)………….. III-97

Table 105: Rest of World Historic Review for Anticoagulants by Product Type – Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart) III-98

Table 106: Rest of World 14-Year Perspective for Anticoagulants by Product Type – Percentage Breakdown of Dollar Sales for Oral Anticoagulants and Injectable Anticoagulants (Unfractionated Heparin and Low Molecular Weight Heparin) Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart) III-99

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 51 (including Divisions/Subsidiaries – 59)

The United States (25) Canada (1) Japan (3) Europe (13) – France (1) – Germany (3) – The United Kingdom (4) – Rest of Europe (5) Asia-Pacific (Excluding Japan) (12) Africa (1) Middle East (4)
Download the full report: https://www.reportbuyer.com/product/98261/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-anticoagulants-industry-300266523.html

SOURCE ReportBuyer

———————

Company – ReportBuyer
Location: England (GeographyCode)
GEOTAG: England

Tags: , ,

Category: , ,

FNeditor